news
Novel siRNA therapeutic could lower cardiovascular disease risk
A Phase II trial for the small interfering RNA (siRNA) therapeutic lepodisiran is currently underway, assessing its ability to reduce lipoprotein(a) levels.
List view / Grid view
Heart attack
article
Clinical innovation: using digital solutions to deliver the next wave of medicines
Rapid progress in digital health technologies is enriching clinical trial design, improving clinical trial recruitment strategies and harnessing the power of clinical trial data to improve outcomes for patients and guide future research. Here, Natalie Fishburn, Cristina Duran and Serban Ghiorghiu, from R&D at AstraZeneca, discuss the evolving nature of clinical innovation…
news
First clinical trial to test novel heart attack drug
The first clinical trial for new heart attack drug glenzocimab, will evaluate its ability to reduce heart damage following a heart attack.
news
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
Janus kinase inhibitors used for chronic inflammatory conditions are only safe for certain patients, advises the EMA’s safety committee.
article
Developing a holistic approach to cardio, metabolic and renal disease
With cardiovascular disease continuing to present a significant health concern, European Pharmaceutical Review’s Hannah Balfour reflects on recent development efforts and drug approvals in the space with comment from Dr Douglas Clark, Head of Medical Affairs at Boehringer Ingelheim UK & Ireland.
article
Generic drug market growth: insights to 2030
The global generics drug market is anticipated to grow to $574.63 billion by 2030, owing to the increasing application of robotic process automation, branded medicine patent expiries and the rising prevalence of chronic diseases.
![Vial labelled heparin. [Credit: SamaraHeisz5 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Heparin-300x278.jpg)
![Vial labelled heparin. [Credit: SamaraHeisz5 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Heparin-scaled.jpg)
news
Increased heparin dose reduces need for life support in hospitalised COVID-19 patients
Interim data from 1,000 hospitalised patients with moderate COVID-19 symptoms shows that full doses of heparin can improve patient outcomes and could reduce ICU burden.
news
NIH launches antithrombotics trials in COVID-19 patients
The adaptive Phase III trials will assess whether various types and doses of blood thinners can prevent COVID-19 patients forming potentially fatal blood clots.
news
Cell-free cardiac patch could improve heart attack recovery
Experiments testing the artificial cardiac patch in pigs and rats showed the patch can reduce scarring and improve cardiac function after a heart attack.
news
Drug approved which reduces risk of cardiovascular events
The FDA has approved Vascepa (icosapent ethyl) as a secondary therapy to reduce cardiovascular events in adults.
news
Frequent aspirin use linked to increased bleeding
A study has found that long term aspirin use increases patients' risk of major bleeding events by 43 percent, with 1 in 200 having a major bleed...
news
Trastuzumab taken with carvedilol leads to less heart damage
A team of Iranian researchers have determined that trastuzumab taken with a heart drug leads to less heart damage in breast cancer patients...
news
Cardiac cells integrated into microneedle patches could treat heart attacks
A tiny microneedle patch could be the future of delivering therapeutic cell related drugs to the heart of patients after a heart attack...
news
Statins study questions their widespread use in the healthy elderly
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...
news
Sensitive blood tests diagnose heart attacks sooner than conventional methods
The ‘new’ test is one currently used in Europe, however the US Food and Drug Administration have recently given approval for the high-sensitivity troponin test...
